-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SJUfCww2KPfIBZIBfnLq3s5Lc9oQYJt/eCm9p6BTD5F2aBTKMh4nf1q4DKn13UTF
 srnOhgB22Il5uN3o0hRTMg==

<SEC-DOCUMENT>0001193125-09-258152.txt : 20091222
<SEC-HEADER>0001193125-09-258152.hdr.sgml : 20091222
<ACCEPTANCE-DATETIME>20091222171817
ACCESSION NUMBER:		0001193125-09-258152
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20091216
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091222
DATE AS OF CHANGE:		20091222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		091255928

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report (Date of Earliest Event Reported): December&nbsp;16, 2009 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as
Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>On December&nbsp;2, 2009, ARCA biopharma, Inc. (the &#147;Company&#148;) entered into an agreement with the University of Cincinnati that gives it an option to license exclusive, worldwide rights
to certain patent rights relating to genetic polymorphisms of adrenergic cardiac receptors.&nbsp;These rights include those for developing and commercializing diagnostics for the receptor polymorphisms that may indicate which patients will respond
most favorably to Gencaro. The period of the option is through December&nbsp;2, 2010.&nbsp;As consideration for the option, the Company will assume the reasonable costs of prosecuting the associated patent rights.&nbsp;<B> </B></FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>On
December&nbsp;22, 2009, the Company issued a press release announcing that it has submitted a study protocol for review under the U.S. Food and Drug Administration&#146;s Special Protocol Assessment process for the design of a clinical trial to
assess the safety and efficacy of Gencaro in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of
which are incorporated herein by reference. <B> </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Announces Submission of a Request for Special Protocol Assessment for Gencaro Development in Genotype-Defined Heart Failure Population&#148;, dated
December&nbsp;22, 2009.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;22, 2009 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;C<SMALL>HRISTOPHER</SMALL> D.
O<SMALL>ZEROFF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Christopher D. Ozeroff</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Senior Vice President and General Counsel</B></FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Announces Submission of a Request for Special Protocol Assessment for Gencaro Development in Genotype-Defined Heart Failure Population&#148;, dated
December&nbsp;22, 2009.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g19552g57s64.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U>
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA ANNOUNCES SUBMISSION OF A REQUEST FOR SPECIAL PROTOCOL </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:3px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSESSMENT FOR GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> DEVELOPMENT IN GENOTYPE-DEFINED </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HEART FAILURE POPULATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO,
December&nbsp;22, 2009</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has submitted a study protocol for review under the U.S Food and Drug Administration&#146;s (FDA) Special Protocol Assessment (SPA) process for the design
of a clinical trial to assess the safety and efficacy of Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman"
SIZE="2">, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company&#146;s investigational, pharmacologically unique beta-blocker and mild vasodilator.
The FDA has previously designated the investigation of Gencaro for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population as a fast track development program. An SPA is an
agreement with the FDA that the proposed trial protocol design, clinical endpoints and statistical analyses are acceptable to support regulatory approval. For further information, please visit the FDA website, <U>www.fda.gov</U>. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Submission of our trial protocol for review under the FDA&#146;s SPA process is an important milestone for ARCA and Gencaro,&#148; said Michael R.
Bristow, President and Chief Executive Officer of ARCA. &#147;We believe that Gencaro has the potential to provide a needed advancement in the treatment of patients with chronic heart failure, a disease afflicting approximately 6&nbsp;million people
in the United States with approximately 550,000 new cases diagnosed each year.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The proposed trial protocol includes a superiority
comparison to the beta-blocker metoprolol CR/XL, which is approved for heart failure and other indications. The proposed trial protocol also includes an interim data analysis at a pre-specified number of primary endpoints, the results of which could
allow ARCA to formally submit a complete response to the FDA&#146;s Complete Response Letter and could serve as the clinical effectiveness basis for FDA approval if the results meet certain predefined criteria agreed upon with the FDA during the SPA
process. If the proposed protocol and criteria are agreed to by the FDA, the Company anticipates that the proposed trial could reach the specified number of endpoint events as soon as approximately two years after the trial begins. The SPA
submission proposes that a composite of cardiovascular mortality and cardiovascular hospitalization serve as the primary endpoint of the trial. Any proposed trial protocol must be reviewed and agreed on by the FDA and the final trial protocol may be
significantly different from the Company&#146;s initial SPA submission. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the timing and outcome of the FDA&#146;s review of the SPA submission, and subject to the
Company&#146;s ability to obtain sufficient funding, the Company currently expects it could begin the proposed trial in late 2010 or the first half of 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
</FONT></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the
treatment of chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing
these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro is well-tolerated in patients with advanced HF. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Heart Failure </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heart failure, or HF,
is a chronic, progressive condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to the meet the body&#146;s needs for blood and oxygen. Common causes of heart failure include
myocardial infarction and other forms of ischemic heart disease, hypertension, valvular heart disease and cardiomyopathy. Heart failure is one of the largest health care problems in the United States and the rest of the world. Industry sources
estimate that about 6&nbsp;million Americans have HF and nearly 550,000 new patients are diagnosed annually. In addition, HF is the underlying reason for approximately 12 to 15&nbsp;million annual visits to physicians, 6.5&nbsp;million annual
hospital days and over $34 billion in direct and indirect annual healthcare costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beta-blockers are part of the current standard of care for
HF, and are considered to be among the most effective drug classes for the disease. However, a significant percentage of eligible patients in the United States is not being treated with, or does not tolerate or respond well to, the beta-blockers
currently approved for the treatment of HF. ARCA believes that new therapies for which patient response can be predicted before a drug is prescribed can help improve the current standard of practice in the treatment of HF. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman"
SIZE="2">ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being
developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating
with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148;
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the timing and outcome of the Company&#146;s SPA submission; the significance of
Fast Track designation; regulatory review and potential approval
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the Company&#146;s New Drug Application for Gencaro; the prospects for ARCA&#146;s providing sufficient information in a timely manner as requested in the FDA&#146;s Complete Response Letter;
and, the Company&#146;s ability to fund future operations. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business
objectives and operational requirements; the Company&#146;s ability to complete a strategic transaction to support the continued development Gencaro, and/or obtain additional financing; the Company&#146;s ability to identify, develop and achieve
commercial success for products and technologies; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in
more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2008, the Company&#146;s quarterly report on Form 10-Q for the quarter ended
September&nbsp;30, 2009 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g19552g57s64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g19552g57s64.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P#7`P$1``(1`0,1`?_$`+D```$#!`,!````````
M``````@`!PH$!08)`0(#"P$!`0`"`@,!`0````````````$"`P<(!`4&"0H0
M```&`0,"`P4#"08&`P````$"`P0%!@<`$0@2$R$Q"4$B%)05H3)248&QT7(C
M,Q8787%"LB0*D6(EM39V0Q@9$0`!`P($`P8#!`8*`P`````!``(#$00A$@4&
M,4$'46$B,A,(<8$4D4)2%:%B(T,D-?!RLE-C<[-U-@DSTT3_V@`,`P$``A$#
M$0`_`)N'(+D-7<#0;9R];C.6>:[Q*Y64%R-SN00*4'$E(N1(J9E$-%#E*8X%
M,=0Y@(0HCU"7KE[B_<?M?V^;=BN[^(W^Z[[.+.R8\,,F0>.:9]'>E;QDM#GY
M7.>XAD;2<Q;]CL_9M]NZ\='$[TK"*GJ2D5I7@UHPS/.-!4``5)X5UH2/-WD3
M-OU%XJ6KU?;'.;M1\;6(YX@B03#TD%Q-%DW:QBAX";K*`[>0>6ORMUOW\^XW
M5=0=/I=YING6[B<L$%C#*UHY`ONA/(X@<ZMKQH."YS@Z5[,M80VXCFF>!BYT
MKFD_)F4#[/FKPERAY1&Z>JYL=CI)KIF"FU@"G253!0AR_P#2_$!*/YA`0UY;
M?=U[N)2!'K%OD<QKVG\ML:.:X!S2/X?AC3X@CDO'=L38#>%L_`T/[:7B#0CS
MJOE.2W**/750&Y,]TRHFV&G58QA!9!)<N^T2'B)50]FO8ZQ[J_=WI-T^!^L0
M$-##_+;&OB8UX_\`G_66BWV1L"9@>+9U#7]]+R)'X^Y8J^Y@<G(=V9-U;8M<
M6ZG2LBI3ZX"8J%V[B*@HQZ*ON&W*;I,4=P\!U\U=>]WW0Z/?FVO]8M#+$ZCF
M/TZS#21YFDLB8[`U:<KAB#0KV,73?8MU%FBMI`'#`B:2M.1%7$8\14%%WQUY
MI)9(FF-$R*P85^UR1_AX.:C!43@IYYL(DC5VKI19:*E%^D>T'<417-[H"0XE
M*;NY[:/?#;=3]<M^G_4NVM].W?='):W,!<VTNY*80N8]SG6\[J'TQG?'*?"T
ML>6L=QMO7I@_0[5^KZ*]\VG1XR,=0R1C\0(`#V#G@"T8FHJ0>?=4_%]@?JU^
MABXB2[JGXOL+^K1$NZI^+["_JT1#QEWE7AK!N2L#XER/:#P]WY'VR2IN,(U%
MB=XF]EXQDDY54F'"0@2%C7#MVV8H+J@)5GSM)(OB81*5`)1#]U3\7V!^K11+
MNJ?B^POZM$0M\@^;'&CBK(P47R`R>3'*]EC7$O$.7U1O$O$*L&KL&*ZSJ=KE
M9F(:-.1R.W:<+I*B7W@*)?'14`G@F'#U>O3<,CWPY>8R[6W5XH6D%1+MU;@@
M-;!80V_Y=%<I5N__`&,]-SI[P<I*\9EU=`RQ:1D\T*4?8)Y@*/\`3B$'\0J=
M/@/CHF5R+G"7*'C[R1C'$M@C,^/,J-69.X_0J-CCY"5C$A%,I596"$Z4W%I'
M,J4"F<-TRF$=@'12A'%/IW5/Q?87]6BB7=4_%]A?U:(AEY!<T>+O%=LBMG_.
M5$QN[<I"NS@).2%_;7Z71UE58U"$0D[*Y14\`*H5KVQ,(!U:*@$\$*T?ZMV`
M;`Q4FJ9A[FE?*P0#'2ME1XD97D*Z[;@'4#ID\=1+%9RV.38P&*D.X"`Z*Y#W
M+&X3UO\`T[WTFY@[/EBXXOG6)^T^A<G8=R;5Y)@H.VQ'S<*P_P#@S^/DH)1V
MT3(5LXH&0ZEE.D57)&/;"SM-'N\(PLE4L<>18C*:@Y-$KAC(-B.T&SHB3A(P
M"!5$R'#R$`'18K+^ZI^+["_JT1<@HH(@`&\1'8/`OM_-HB';`7*S#/)ISEQI
MA^TFL:V$LG3&)KWULC,R(6>%3(=9U%*'$Q96O/3]TC5\GLDX.W5`OW!'14@C
MBB([JGXOL+^K11=BJ''?<?(IA\@\P#P]FB+2)S.>2$YR.M3)PJHJWA(RL1;!
M,1,9-JS/"M)-0A`'<J8*O9%4YO+<3:_!'WTZKJ6K^Y+5K.X<Y\%C:6-O"W$B
M.-UM'.ZG(9I9Y''M)7:KIC%#:;*@E8`'RR2O<>9.<L%>VC6@!4&,\<-9X4&1
MC(-)-7I+'J.3%19/E3?<8.5C"!&;E41V16,()F-L13IW`X>DZ0=)K3<^2"[+
M(=6>0(7/(;%,3PA>XT$<CCA%*2&.-&29:AXNX->DLZO;5T`\U,7-'X@.8'WA
MQYBN(18PV('$G5W;7Z6NC8ZB]^'<QZC<Q7JT-)"<X%%$2]9E(R1*H8-@'=)<
M=O`H:[JZ)T:GU+:<UI%9O9N?19\CX7,/JOM9ZD#+3,703!Y%,#'*2,&A<;W.
MXFPWS9#(#97+:AP/A#V]_8YM/FT=JS^RXA086*PV%RR*,/7X>-?-Q43_`'#^
M8")9,8UFF(ATJE3E"=Q8`WV*GTC]X-<B[KZ.PZ=N?4]R7MNTZ)IME!,S,WPS
M7/T\44,8/W@)P'R4X-9E/F"]19;B?-9PV;'_`,3-(YIQQ:S.YSCW>'`=Y[D)
MMXQ3]+CBR<T@9)U($,O&1B@"5Z\2,8>J4?D'95I'&/OT=0`HY-OT@!`$^NF7
M43HI%8:7^<ZU$67UPTR06[L))02:SS#S1P$^6M))W5RT8'/7(FD;C,T_T]NZ
ML;#1SN0_5;R+NWDWG4X(/)AH]K\D209G.W=1[M%\V<([IF;.VJQ7#9=,2;=H
MR2Z91+Y;"`:Z1W;-1VWJPN;=SHKVUF;-&]N!9)&X/8X$>4M<`6]E!1<I6TD-
M[;^E(`Z-[2T@XU#A0COJ"I&T*\4D8:'D%MN\_BHUZML&P=UVR0<*;![`ZU!U
M_4'H5[)J6AV6HS4]:XM(9'?%\;7'])726[B;!=2PM\K)'-'P!(5SU[5>.N0`
M1$`#S$=M$4$?U:<O9:S;R/4Y@5199#!6.,PS''#CK<&3I0S52WX%/%VRRV-B
M5,B?2VGKL_=KM70#LZ3CQ3`?]..JMS104YJ9SQ7SQ"<G>.N'L\P(I$:Y*H\1
M.R#-(=RQ%D(D+"V01O>,(*0=E9NVIM_']UO[=1:B*&B?[114SUDRDF;B/DF;
M21CWB1T';!^V1>,G2*A1*HBX:N"*(+)*%'8Q3%$!#ST10!LF8HQVQ]9F3P\T
MJ4*WQBXYRU.OGHZ+%!*N%KLW>:\]D:\E%ID!JE!K&D%4OA2E!$J!NV!0)L75
M6X>7Y*?-_*M63B#5LE9KI*\#?X$($L)%A#?!%(*)6GTL&OP7PP)>[V^CIZ?#
M;;46E0E?5^Q2TX`>H!2LI<4'BN&9"\4:*R]#,Z5_T>-JUP;62:K]D91D<W$K
M,*K8SQ2+AU%&(+!07*Z7:!$P)EJVM.88J89Q:S&IR$XWX.S>X8)1;W*6,*A<
MI2-0`P-F$Q+Q#9:9:-.LQC_!H2O>*CU"(]H"[^.HM9P-%J%]9;U5);B3'(<=
M./\`(MD>0=P@DYBTW$$F\@.'J=)@H2.6CV2R;ALO?[0F0YF)5B&(P:!\49,Q
MU6VJLFMKB>"JO2V]*NNX\KL/RNY=Q!\M\J<G(-KJDEDXQ[>;%S.92^.CBN23
MQWXRF2W35R59^_==Q2.5,#5J"0I**+$<[D%OK`PE``*(E*```%+[I0`/````
MV```/8&HL$"G.?@!@_G/C.9K5XKL1$9-:Q;O^G&7V,>@C;J;/D0,,9\1)()D
M>3555=%(1]&.#*(+("82`FL":I"R::'N6*^E'$7^I<$\-8WRE6)RHWW$;G(&
M*+!%3L:_C53FHN0[/#QLC&A(-VZC^"D(A-NHR=I@*#IN)5$S"4=]$=Q6Q318
MH(?40Y&/>,W%>^6ZKCW\IW9:*P]A.*2$XNY7+63W05BI_!II[J*GA#NU9-0`
M_P#B9&_+HLFBI[E&#]&/)URX;^HY>.*66%ABELHO+%ABY,W#XR[1'+U"=R4O
M3I9)T;I*^&<,G(,FZ^V[HLJB8-]RZJS=BVJFM:BU+N3S-^P;]&B+35R-CWCK
ME#?5&:+M0X#5R@9JDJH;?^587<H]HIM_`0W#RV'7X4>Z/3M1OO=QKQL8YW.;
M]#C&UQQ^@ML/"#VX@_,479S9D\4>P;02EH'[7B1_>O[41F+JFXDD$$IW'DPZ
M2.!`":A&+F'?)>`>^LB9$(9Z'Y1%-)0?:<==L.E.SKG4;6&#<&VKV:W(;6YM
M8GVTK:TQ<TM%K+WU8QW/.5\#KNH,AD<^UO(VN'W'N#VGN!KG;]I'<KK/Y"DI
MZ^2U,:2CQO7Z<[+6#&!4B,C-N8S9)VZF7C8$E71$7!C)))"/;*4G4("<PCKV
M.X^I>I;CW]?;&L;N>+;FAW'Y>3F#9[J2"@DDN96!KGAKRZ...N0!F8@O<XK3
M::+!9Z3'J<C&NN[EGJC"K6!WE#`:@5%"3QQIP"?V.;,H2%2?LGP&4)T*J,5U
M!79N>V8J@%<-U1,D8.HNX&VZBCX@("&NP^EVUAH&@-U2PN:S-H3"\YXWTH:/
M8XEIQ&!IF::.:00%\C,^2ZN3%*S`_>&!'P(Q_I0IOLCUU"11/88^H6&WOIEL
ME(FDI`SES$,RN$BG(W09Q!4%G7P91!,`4.5,O3MTF\=<?]2]MV^I,.Y=+T74
MM:U"_B;,9YB]]M$'M!#&Q6P8Z3TQX`)'-8`VF5P7MM&O'PGZ2:XAMHHG%H:V
M@>:'$ESZ@5XX`GO"UF9@B)@JCHSV-=M`*57I;A&'CVR(`4?!-LF@BB0"E+Y[
M;_E'7Y.]=]$UV#4'RW=K/"QN8A@@,,;<#PC:QK10<Z5[25SUM>YMG-:(GM<<
M,<P<3\222MY55_\`%JS_`.NP?_:VNOZ#]H?\3TO_`&ZV_P!%BZHZC_,)_P#.
M?_:*OVOHEX:UX>J+R9E.,?$2\2]*.JMF+*SN/P?A&+9B)I-[D?)(JPS%['I$
M."QG%>BSNGY!*!@[S=,H_?#19-%2A9Y,>G/'M?1Z3XI5UDC)W[!&-(O)M?>H
M`0Z\SEVFIO+C>7""I2=QRO<EI*:9$$1$YBO"`(CL&BH/BJ@O_P!M_P`G"R]0
MS!Q-G9#K<U=V3,^-$5S@!SURQK-(B^Q34#F`_:B["#%\!"@.QI14WL'5*KQS
M4H746M+1%`KSI.PE7]<BQ62RR\;7Z[`<ZJ1,3L],O6\;#PT3'V6J.7\I*2+M
M1)JPCV+9,RBJRIBIID*)C"`!JK:/*IEMEYS\+ZI"N+).<KN/;>(026<&<-<M
M4J67532`QSE:L(>8?R#U?8H@5-%)10X^!2B(AJ+70]BC7\AL'9J];OFE$Y$Q
M#4+1CGA]0JQ#8VB,_P"0*Y(5EE8:S'2\I/6:RTB#F$VLG:I>>DIA5.+;I)@B
MD@DBJ]4;]9DPJV`AH[U+`QACJJXBQW0\54AD:.IN.JG`4NM,E%`460A*Y&MX
MMC\2N!2=]VHW;`=940`5%3&,/B.HM9Q-5`NPVY/S<]7VJ2]_#ZM&Y0Y8REEE
MF#PXK(*TVARTK/P];V5$P?3D:O36K`$_+LAT[>.JMO!OR7T"1'<1'\HB/_'4
M6E<:(EHBY$1'S$1]GCXZ(N-$6E2[/PYH>K51,8-A&1PGZ<%7#+%YZ-U(N8Y+
M7]L1I1HI=0@&25=4N',5XD4WBDY;.B#L(Z+/@WXK3UZ^.%I_C[S,Q1RZQSW(
M13*;2#L",PT*"*<9FG"[N)%!X(H]($6E*^G$K^.QEC-%Q'?QU5DTU%%+`XTY
MP@.2F`<1YWK0IEC,GT>$LRC5,PF"*F%VX-['!J"(B/?@;"W=,U-_$#H#J+61
M0T3YD\S?L&_1HHM,/)5<Z?*"_%((`(?RN(F,H1$A`_E:%]XZJAR$(7^\=?@_
M[K)98/=MKSXS3"PJ2X-`'T-MB7.(`'Q*[0;(8UVPK2O^+W_O7\`GXQ9.5Z+*
MU6D9N:E'/40$XFM+.&R!CCL!".)=PH@90#&$`Z&Z)^K?P/KLSTGW!MK2X8+O
M4+^_N[GP@6]B]\;"[@`^X>YA-30988W5Y/7Q&O6EY.YS(HHHV?CE`)^3!7[7
M$=X7AE/&%^@[],7ZCPKBP1]F,A/V6J1*Z<A9:?+/$R_%E<L$^A=ZR>J)"L4R
M13*I*&,0Y-@*8WK>KO2CJ1MSJ1?]2>GUA)JFD:N67FH:;;O;-?Z;<R-'J%T(
MRNEBE+3(#&UTD;W/8]F7*]V_0-=T:]T:+1]5E;!<V]8XIG@MBF8.%'<&N;6G
MB(!%"#Q`OU3-DNU$3:NJ_-52%*=)*2L%J8N82/CDE%")"?H?E;N':XF.`$33
M((&,(=0E#<0^DV:>IV\6,MKS3=1T;0@YHGO-1A?:0PM)#2:3!CY'U(#6L:07
M$9G-;5P\+46Z)IY+V30W%R1X(XG"1SCQ^Z2&CM)/#@"<$X.4I2!9$)77B]BK
M3J*8-6C)VFY-+0<G'H(E29/SM$%VRR17:)`,*C<%/>$P"4P@.N3>J^I[=L\N
MV;V35-*NK*WCCBD;(;BTGA8P-BF,;71N:)&BI?"'^+-F:YP*])H4%W*3>1B&
M=DKB2",CVN)JYM2"#0\G4[C1:T<L.?>==+M!\ETJ=+ALX,JF;<HB`'(J5)RB
M;\H*$*.ORAZV7;Y[^1L4T=Q!4^.-Y<.=*AV5[#W/8W'M7/.V8Z,;5I8X4P(H
M?T5!^1*WMU3_`,6K'_KL'_VMIK^B3:'_`!/2_P#;K;_18NI6H_S"?_.?_:*O
MVOHEX:CU9YJ\KZDOJF-<+5C(]TQYB7T\Z6G;9W(..UH<)R/Y'6V1CG$4G`N)
MZ%G81&:@DF**/4X:KF0-%/2DZ#'Z@+,>%M>91XFX!Y1.`E/ZDO/$Y#`)3D-:
M<.&*8I@V,4Q38@$IBF`=A`0VT4S=P459I'27I%^K9#-'LI*R%`I%\C2.)^4(
MV!]:,"9>CB,Y&7D2L&S*-<2$0PEEE5@1120"2B1Z"$`H%+>2V>9JGDHK(.$D
MG#99)PV<))KMW""A%45T%B%416153$Q%$E4S`8I@$0$!W#46E>FB*!AFR*BY
MWUSYR$G(R/FH67YWT6-EH>69-I**E(YY9ZH@\CY*/>)+-'S%V@<Q%452&34(
M(E,`@.VJMP\JWL^K/Z2>*,O84G<N<8,0TZ@YZQBU<V%2"QS6XRKLLL4^/045
MG:NZ@8-LRC'5N:-""ZB7)40<K+)"T,)BKD[<6#74X\$,WH(>HI]68->"^9+`
M<9:*0>O^.D_-.!!1_"MDE'DSB-9=P(*?'P*2:CR%3/[QF0+M2[`V0(:E5[>8
M4I$H[&*(^6X;_P!WM^S46M?/KQR!N"/JYP+>_P#5$0^(^5TC%S3]TF*226/K
MQ+R44QLP=P"@,>>E7)"0*?R[0;^S56XXM7T$MP'82F`Q1`!*8H@)3%$-RF*(
M>`E,`[@/M#46E+1$M$5L1FH9Q+/8!O+Q:\[&LV4C(PB,@S5F(^/DSN4HU^^C
M"+&>M&4@HR6*@JH0J:IDC@41$IMB)GN36>*SQBP#E?/=N,F,/C*G2EA39J*=
MH9F;*0&E:KR)]P$'-AL+IJR3V\C+@/D&BH%31:7/3KX`9<N7']ER8MG+SDYA
M++/+>7D\\Y)@\3R-!AXJ15MLG)2%3?206N@V697?*UMZFX`!<E11(Z!,B9>D
M1-5DYV-!P"[>I1Z95_M7$;*-K6Y;\H^0%CP]#N,KU.@Y8E<<2U;=.:N@J>R+
M(I5S'M=F22Q*2XDOANTZ`IUNDIB'`=@(UV/)-3_MPN2PV+&^8.*DY(`J\Q[*
MHY9QVBJKU*'I]R<%C[A'M"F-N#2%MJ2#L0*&P'F1'0H\<U)N)YF_8-^C46"T
MG<V(:3KW(:<EG"*A&=GB*]+Q3@2B";A!I%MH9X1,WD91L\CS`</,`,41^\&O
MP:]^6W-3T3W%7^K73'-LM5L[.YMWT\+A'`RVD`/:R2$YAQ`<TGS"O:?I;=07
MFSHK9A!E@DD8\<P7.+Q]K78?`K%\;Y-&N]IRV.7ZL`;-7B@`8(H!`0%PT(<!
M(:2$/N*B`@AYD#N;&)\-TGZONV>YKF$?G/[N4XBWY9XP10S_`(9#40\6`R4<
MSS->V_\`75:X?P_,#[_<3^'M'WN>&!*.*RP$94CLD7AAE+.[^IRCHRQC."Q;
M(3I,&YE3&%0QW[WO+J"([F(4GL,.NXVC=7X=.V:ZQM+D_FVK3>O</+JO%O%5
ML+"XU-9I?4E>2:EC65P>5QW<;>=-J(D>S]A`W*T4PS.Q<:?JMHT=A)[$X%CS
M&V<6J>CWCTH0]CAXR(="93=-LZ/#LEF$B`=6Q?@Y0X&./M2,?^S7(VY^M-G<
M;NU'3[^Y:-#U2R@MWU=41R&VB=#/3@/3N"'./-CG\Z+U%EMJ5MA%-$P_4PR.
M>.\9W!S?FW`=]$*MQRH=:.-!2BIET6)UB,%#&ZW<,N)A!PBW.([GCU52_O&X
MCT]0=:?2;?JZ;[]ZU`Z6=LZB]\D4!>(G>:2V>31[6'[T+G#]I"3E!\<9:^N;
MD/2]N4F%Y"`'/IFY!XY$]CJ<'<>1J.`J.`DK=.,H:,24?2,S(-HJ/00*8YW3
MU^X(U;))E``,('54#V>`>(^6NHD-GJN\-P0Z58,=/JU_<LMX&-!)?),\1L#1
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M*0,8Q2%,8YBD(0HF.<Y@*4A2@(F,<QA`I2E`-Q$?``U%@HB?^XX_H/:I[CKD
M*FY'H5BRL@TMV/;C6JW9X2=F!HJ0(6&O2\RUB7;I6-;14XZ>MDC..@5AD!!/
M<$S=-"V,KS6Q7TB/4]PGF#CGCS"F7\IU6D9[Q)7V%%<L[W88VO$R'6H`A(VI
MV>LRDNNT8S$@:#30;2#4JIGI'B!U1(*2I#C%'--:A;EKMES%&-8I*<R+DW'U
M#A7#,T@WE;C<J[6V#IB4A3B[:.9>1:).VXD,`@9,3`;<-M]PT6%"H"62^1.*
M9'U:);DO'61*0PZVYE5O(9+4T1<*)/*/7KG!@\LK-IV@?+,56$6H[1*"7=40
MZ1`FX@&JMP'AHI\>.,V8=S&Q2EL394QYDE@NT3DB+TBX0%E,FS6[9B+N6\2_
M=.68%%8I3`J0AB''I,`#X:BU4(XJ'CZU7"&;X?\`(6`Y=8'2D:GCC*%R1LQ)
M.M=;'^D>?&3L]@/].5;`!(J/MJ[4TM&[=*9'R;Q`"@0$2&JV-=7CQ6]WT]_5
MOX]\J,45..RKE&@8OY'1,:A%Y`IENFHRFLK',LBD;&M=$=3+EI%RT18PZ7'P
M:"QG3%<ZB!T^@B:BD6!:1PX)D/6!]+)7FE!QW(SCP6(>9ZKE;;QLE`$>L6\3
MFVC-B*.(IHTF3+$CD;E")+G"-<K*`W?-5/AE5"`1N<A5KJ8'@FO],SU9HJHP
M\/PTY^N93!^;L8I,Z;5+QE5D]J[*VPD>4C"(@K\[F4F_\LW.&:D30)(.^B/E
MVQ"*]\''5WJJYO,<%(MBY6*G(YM+PLI&S$2\1(Y:2D6_:2$<Z;J%ZDUV[YHL
MLU614+XE,4PE$/(=1:T!?,KU+^*_"VI3#^\Y`@+9DA%FZ"MX:ILW&RUYGI<B
M?^D:R;=HLY2I\.9<Y>^_DNRFDD!A3*LH!4CED&D_!!)Z+F0;%F:C<M^?.<IR
M!CK+R#S<VAE)9X^;QM=K-$Q/7FD77:S$2,HN1-G6:^]LKAD@"BH"HHW%13=4
MQQ$J[D`@E]8KGI@;D7E3CWPFJ66JX]P@7,M&G^4.4*]+H2-29,`L+.*;UMO/
M1XK,I)K5XAZ]E))9NHNV0<`U#J[B"I24*M!`KS4H*@67'%CK4;_2RRTVRU")
M81T7$K4:>AI^#91C1FDA%,VSF$>/6B;=-@B0$B@;84RAMX:BUT(XJLN%HHU6
MAW#G(-DJE:KKQ%RR>.;C-1$)#NFRK=0'K59>:<M6BJ9V@F[A1$0Z-]PVT3X+
MY_6$^0M)]/KU*9O(V*K`C?L'T#,&0J0H[J[UO((7+!D_+O8MP6%6(N1E+KQ,
M6=N[8F!3L.7D:D8I^@P'U5N(JWO4Y:F<SN+60,3V+-M'SA0;9CRI4.Q9'M+^
M`FD)*;KE1JL,ZG;$_G*>V$]LBW4/&,E#K-5F1')3%Z>@3"`#%JH>"S[->%*=
MF^O!`VA-=J\8*'<P-ACP2"5@WBB92*'0%4IDW#-R!2@NW/[BH%`?=.4IR\+=
M<.A.RNO.UV[>W6V2*]MW.?:7D.43VLCA0EA<"'QO``EA?X)`!Y7M8]OT>V-T
MZGM6^-W8$.C>`)(W>1[1VTQ!'W7#$=X)!URRGI_98CWRH5ZX4F68=9NPY>K2
M\*\,GN/2+AD6/DT4U-MM^A<X?VZ_,?7/^MWJU:WKV:!K.@WFGU.1\KKFVEIR
MSQMAG:T_U97!<V6_6/;TT0^MMKJ.:F(:&/;\G%S2?FT*K3X6<@"#N,U0!]TI
M`VGY<`*1,A4R$*48'P*4A0`/'6#?8-[C6.S1ZGMT8``?575`&@-`'\'P``6M
MW5#9Q_=7G&O_`(V?^Q5DAPXY`OU5%3S-"W4*F4>JP2NX`DBFB4-P@?'8J8:\
MW4_8G[D=4G=--J>W@'!HI]5=<&M:SC]'V-6J#J9LV%H:V*\P_P`-G,D_WG>K
M"XX(YTDW/6]L./T@5$.ZL,S,K>(``&4,0D#UG.;;<=MMQUZA_P#UW=>-0O/6
MO]2VX'O(S/-Q=.Y4+B!:5)/$]I)*\QO5S:=O'EA@O#3@,C!\J^HBZP!Q"J^'
M9!"VSTF6XWE%(Y6+SX06D)7Q6(*:RD.S5.LNL^.F82?%+&`Q2&$"$3W$1[L>
MW/V8;4Z*:BS>.X;H:WOUC"(I?3].VM,PRN-M$2YSI2TEOKR',&DAC(ZNKQMO
M'J1?[FA.G6C/IM*)\3:U?)3$9W"@#:XY!A7B3A0PM=UEQJAH?\,.(4M9)ZX2
M_%[`,S:[3*/INR6.8Q-29::GIB37,ZD).5D9"&<NGSYZY.91110QC'.(B([Z
M*U*4;PNX@PEH@;M"\7,`P=PJLJQG:U98;$U)B9R!F8Q<KJ.E(F180S=RQ?,G
M)"J)*)F*8AP`0'<-$S&E.2)%RW0>-W#1VBDY:NT5FSINN0JJ+ANX3,DN@LF<
M!*HDLD<2F*("`@(@.BB%6*X&\(H3;Z7Q$XVL]@V]S#-!/OY_>%6"4ZA\?;OH
MKF=VKUE>"G">;2%&5XC<;GB0E,04U,,8_*7I,`@(;)0)/'8?/ST3,>U93=N)
MO%[)84\N1./6&KR3'U<;T^BDMF.ZQ/IU&J-`0*TKE>3DXYR2*AFI6R8)MT0*
MF0"AL`:)F*LY>%7#@J(-PXH<<01`O1T?T6QX/N_DZAKXF^W1*GM618UXM\:\
M,V9Y=,18$Q%C"VR,2O!/['0J!6JK,O(5RZ;/G$6Y?PL>S768KO&2*ITS")3'
M2((A[H:)4E./?\=4+*M6?TC)U*K&0*9+*,U9*K7&#C[#`/U8YXC(,%747*-W
M+-91D^;IJI&$HB10@"&PZ*<$Q+K@SPK>LBQSKB1QM79%#8J!\+8]$H!L(?>"
M``X^`_ET5J41=9K%=I==@ZA4(.*K-5K,4R@Z[78-BWC(:#AHUN1K'Q<5'-2)
MMF3!DV3*FDDF4I"$```-M%$VV8..V!N0,82(S?A['.5&2*2B#7^=ZE#SKQ@D
MKOW"QDF\:GDXSK$=Q%NLF._CHJ"1P0=D]('TZT!.1AQY"(9*&$RD1!Y3S+"P
M9Q,(B)30L9D%M&=O<?N@ET_V:*YG)VL>^G3P2Q:?O4KB;@UB[ZP5^I2]%BK;
M+F5+OTK'E[>G.R:BP"._6943;^.^BF8H@;3A3#MWH;C%EOQ9CZQXS=.&CMSC
M^6J,$ZIJ[I@^2DV3A6MG8_23JMI!`BQ!%+<%"@;S#12IXIKDN$?#)!H#%+B;
MQO(U`@I@B7"V/.D"#_A`1KXF`/SZ*YCVIQ\4X&PE@IK.L<+8EQWB=E9WS62L
M33'E1A*DUFY!DW,T9O)-O",V:3MPU;',1,QP$2E,(!YCHA)/%=LK8)PKG5A"
MQ>:L3X]RQ&5R16EX"/R%4X:V,H>3<-3LG#^.:S31VBU=+-#BF8Y2@)B>`^&B
M`D<$W+;A/PV:(@W;\3^.":)0V`@86QX8`#;;8!/7S&VV_MT2I[555KAGQ&J$
MM+3E4XR8(K4O-UBPTZ9D(+%M.BG$O4[2R^GV6M21V42B#Z"GF'[AVU4`R+A(
M1(<HE$0T2I[42RO\0WYO\H:*+ST1+1$M$2T1+1$M$0U<KK?,5'$Z@569FX>Z
MV2Q057IO\ON46T@^FI5UVQ:G,H@X5%F#(JIC]H"*`H!-CE]I9-%3W)V,:P2%
M2IT'3QG!GYBN1S9O8WSB4&5DEYUV!GDH[DE55UW9%7L@LJ<@*B`]&P!X!HH>
M*N%\:OG]0GXV+MJ=%EI1@K'1-L4!J88:2=[)M'"2;Q5%%583CTE*!@/X[E]X
M`T0<55U&*F8.KP$-89]:U3D9%M6<K8W#9-FO-/44P*L_4;)"8B1EC>S<1';<
M1$1'1#QP5V3D8Y9ZO&)2#!62:IE6=1R3QLH_;(G$`(JX9D5,Y13,)@V,8H`.
M^BBJ%54D$E5UU"(H()*+++*&`J:2*1!4554,/@4B9"B(C[`#1$V.+,O5'+T&
M:>K"CALW,_DV;5C+*1R$L\;1;D6IY=&.;/G;@L8Z4`>T<X$,(%'<H>&Y4@A9
M]..VC"$F7[]ZM&L6,5(O'DBW,0CA@U:LUEW#U`ZI%4B+MDB"<@F*8H&`-P'R
MT4"%/B._F7U#D\BWRV24C)9.M;TU9/;)HBCLU:A5EHV$8L4ESMVP*JKF7.)&
MR293B8!Z?+0K)U*T",#18JG>.VD>T7?R#ILP8M4S*N7KU=)HS;I%^\JNY<'3
M013+[3&,`:(NZ"Z+I%%RU62<MG*2:[=PW4(N@X05*!TED%DC&3625(8!*8HB
M4P#N`[:(J(9J&*V,]-,116170L3/!DF0-"O04[0LS.17[(.P4]WM]77OX;:(
MKEX``B(@```B(B(````;B(B/@``'F/LT16PTU"D9)21IB)+'+J@@A(&DF16*
MRXG,D""3L5P;J+"H02])3";J`0VWT15*CYBD[0CU7K-*0=)G6:L%'2!'KE%+
M?N*MVAE`<+)I[#U&*40#;QT156B*BD)*.B$".I:08Q;91=%LFYDGC=BW4<N#
M=+=N19THDF==<W@0@#U&'R`=$5;HB[D\S?L&_1HBY5_B&_-_E#1%YZ(EHB6B
M):(EHB6B(%;M&RN>N3C&K1DJ[B:3@2,!_8IF/,!'9;?84M_A8ER8!39S*3(A
M$TW.PF9=E90FR@$$*LQ@WO*R#CE2J\WRAF/(=!C1A\:2'T>D5?H7=N6]JD:X
M8QK/:V[EXNX7?-%);J12=&.?X@_=.!AW$1*..`!XK&,ZP,;EK.=,Q6K(K/&$
M$XB;Y?W[QTFA&4JNM3(M86L11"]ILWFKG+N2F675[CI0%6Y"&!,@$U%6X`E/
M+R?R!9:/C]A'TI0S2Z9#M4/C^MORA[\2YG#*%<R26X"!7+9HD8J)O,BAP/YE
MT4:,4S%JJ,7C[*W%K&&.R&-:8Z=E[;=YTNYYV8KH,2L[%+6J3$3.WI+"J#D1
M!<YB=29"EVZ2`%5K4$E.7S"GG43B12*AY"7;66[3L;2JTPB)%2//*/YXXMET
MG_PQ?BW3!!AW1,D4Y"'4,0%.HONC%&\4R]XQA`T3)W$.BX\AXZ/O,4_%_9YJ
M&9I-)-_5X)M%ISLE/NFQ$UGK1\LF[V%<3`.YB!][8:L@:@UX)ZN8%CDX_$QZ
M;7$U'%IRO8(K'L$S0/TN5RRJW>DP3V\0(=BW%$YO(@+[CX:BQ;QJF&SC@6-@
ML4XMI#=,E@R[/VZDU&`FP[Q589I&M%G,JUK+?KVA*M",6QE51(`&5,(N%S&5
M-U!50ZIKR1FY0R"&-JY$E9-0L%OLLM%TRCPJZPHA.VB1`$&ZK]8NZB,8R3(9
MT\4+[Q42"`>\8NHL0*_!!YF2"K]UN=)P0^G!MUXE)%M:\S7Y\Y[+:JTZ%3-)
M2,)&-@7",K$?)`()I,R`4$TC)"N9157N#5D.WER1A99<P56Q59I!^LYB:S5H
M+XQ>/B5PCOJ$;%)%(SJH.$B]]I'S*A46:H(&35,B<2%.7J$=18CCWH0^.O&.
MOW###)UER,<O6]LD7MKK]9;/'\.RKC:56063EVR#)=#IEYILU2`%#@846`)I
M$`O4J)JLBX@X)^N4,['4_$#PYU'JIG!D:Q7:FR,82VZ<E&:L;!Q#_H`S]Y&1
MQQ^,6;IG+\7\.":HF(82'BC14H)+;A-]"8]Q!QZ*V0L68[X]^NKIN3*+1>+J
MLFZ4DIA9F@B;L,U7#M00?/0**KKL*IE'H*B4*L@>?)/92J'7[-R6C'3!ZK(,
ML$,"0\_>I%R`S60LJ2$<L/T4C@RH=4=6(ENH(,FX=MJFB9,`Z#"82$X?%%'D
MB^2D=/U/&5+.V#(%]^.<-W[I(KIG4*I$E*:=M[UF80*]<(`<$&#8P@1P\.'6
M/;(<!BP`YG@A62@Z)E+D76JY`[3=5PJH,]>[K-R*DH\O&1':I$*]!N9-TH9"
M3-'R+0RI$DRE1!1)9-%,J90`:LN`[UL*'Q\1\QU%@NY/,W[!OT:(N5?XAOS?
MY0T1>>B):(EHB6B):(EHB'\G'.I)V>[SQ+)>4(G(LJ6:N-,:3B+&NSC_`*5"
MJ%>+LV*-@^G.`6."C4CTB2A3B0X&)[NBN8I]F+%C%LFD;&,VL?',&Z31BP9(
M)M6;-J@0$T&S5NB4B2""290`I2@```:*)H8'!%+@LA6W))G$Y,S=NF6L\X8S
M#Y)Q!QLFP1,BP<L8U%L@59:.(H<&IW)EQ:]6Z728`-HLLQI3DLROE"A<@QL:
MQEE';1S!6")M5>EX\S<LC"6&$7[\?(M0=MW31;I$3$42634253.)3!Y"!0&B
MM].QA`5";G[9\3*62[6KLISMPL2S=S,.6;;I!I$,4F;9G'0T(TZ0[;5JBDGN
M`"?K,`#HA-<.2&BYL"YRY11-2;3#MG7,#UD+.\D89PS4<-L@S3MN>*[7?1>,
MU5HXC=$RB2R:A/W*B9P]X0U5EP;\43E5QQ"UF<F;:L[DK+=;`BBTE;=8%&JL
MH:,;#UM86-08M649"0C=01.#9J@D4Z@]:@G/[VHL2<*<EZ6#'-?LUTI=YEU)
M):4H*<T%=8D=)DAT7<ZW(T=2CAF*!E%I)NV)TH*`H4$]]^D1T2II166AXBAJ
M.[^IK6&WW>90^J(Q,S?)H9Y_7X^8=%=R,;"'%!!-D@\53)WE.DRRI2%()^@`
M(!":KRRGAJO996ISN9FK1`OJ/-+3D)(5243BGY'+A)%)8HNCMG)T!$&Y!(JE
MT*IB`])O$=$!HL:B>-.-(:_/+\T3FE%WL=&,%JZZDOB:ZN>*4;N49"1151-(
MS3U61:D>*B\<+D4>!WCE,?I$I,QI1.'DK'$!E:LFJ-H7E20:TI%2CYM%/",C
MR7TET5ZC'/E#H+BI&N%R%%4A>DQND-C!MH@)'!9TDDD@DD@@FFB@@FFBBBD4
M")(HI$!-)),A0`I$TR%`"@'@`!HHF^M6,*W<[?1;E/J2CIWCQT]D:]$%=ID@
M?JSPA$RR[]C\.95V_8@F44#=TI4Q*`[#X[E02%S#XPK</D6TY2(K*O[;:XV/
MA5W$B\37:0\/'%3[<9`-B-TA8-5UDBJJ@8RACJ!OOXB`DKA18UBO!%,Q,+Y>
M'<SDY(/I.7E2R5F?)2#A@XG%$CR8QJ2#9JU:K/BH)E77Z!<KE(!3J"4`+HA<
M2NMTP35+UD&%R-*3%NCY:(@3UI9C`3JD-'S,*HY7<J1\HHT2+)"U<&='(LFB
MND59,0`WEOH@-!1>&/./E!QM8)ZQP@R[QS-3KFP-F$FZ0/#5UZY16:[P46T:
MM6Z"C9DN=NBLJ"JR+<PIIF*!C]14N)3Y:+%=R>9OV#?HT1>Y_O#_``?9]_[W
MD'GHBZ_+Z(E\OHB7R^B)?+Z(E\OHB7R^B)?+Z(E\OHB7R^B)?+Z(K9-;?1I?
MJ^D]/TN0ZOJG7],V^$6W^H]K]Y\!M_&Z?>[>^WCHB"S"7P?]2T^C_P"G_=[<
MAT?T=^O?SU]UQOW^_P#Z3M=/\;N?XNK;QVT6;N'-'-\OHL$OE]$2^7T1+Y?1
M$OE]$2^7T1+Y?1$OE]$2^7T1+Y?1$OE]$2^7T1+Y?1%V+[?X'W1^[_=[?^7\
$NB+_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
